← Back to patent-cliff list
RTN-001
Tier C — Watch / tradeRTN-001
Retension Pharmaceuticals Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：PDE5A
Indications (approved)：Hypertension
Regional status
US
Phase II
2025-10-31
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of RTN-001?
Approved indications include: Hypertension.
When does the RTN-001 patent expire?
No public expiry year is available for RTN-001 yet; this page updates once verified.
How do I get a quote for RTN-001 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30